Pathogenesis, Viral Dynamics, & Immunologic Response of Hepatitis C Virus
July 9-14, 2000
Most people infected with hepatitis C virus (HCV) do not have any acute signs or symptoms of hepatitis. They usually remain unaware that they have been infected during the first 10-20 years, unless they have a blood test. They will usually be found to have some elevations of liver enzymes in their blood, as a result of leakage of these enzymes from damaged or dying liver cells. Specific blood tests can determine the presence of antibodies to HCV, or measure the blood level of HCV RNA, also know as viral load, by polymerase chain reaction (PCR). HCV RNA is detectable within a few days after infection, and antibodies usually become detectable within 45-90 days (Seeff 1995).
The precise mechanisms by which HCV infection causes liver damage are not known; however, there is strong evidence that a person's own immunologic response to HCV contributes significantly to this process. The process of inflammatory changes seen in the liver over time results in the formation of scar tissue -- fibrosis -- that leads to cirrhosis. Cirrhosis -- extensive scarring of or fibrotic tissue replacement in the normal liver -- is responsible for the life-threatening complications of HCV and hepatocellular carcinoma (liver cancer). Carlo Ferrari and colleagues write:
The final outcome of infections by viruses that cause chronic diseases is believed to depend mostly upon the rate of replication of the infecting virus and the capacity of the immune system to mount rapid, multispecific and efficient virus-specific responses to inhibit infection before the virus can devise strategies to evade immune surveillance. (Ferrari 1999)
HCV is a single-stranded RNA virus which does not integrate into the host's genetic material. HCV must constantly replicate to maintain its presence in the human body and is very efficient at replicating inside of human cells.
HCV Replication and Kinetics
HCV infection persists in 70-85% of people infected, despite evidence of "readily detectable, multispecific, humoral and cellular immune response directed against all the viral structural and nonstructural proteins" (Chang 1998). HCV replication has been detected in hepatocytes (liver cells) and in peripheral blood lymphocytes, but not in immunologically protected sites, such as the testes and brain (Chang 1998).
Laskus and colleagues searched for sites of HCV replication outside of the liver in HCV/HIV coinfected people (Laskus 1998). They found evidence for HCV replication in the lymph nodes, pancreas, adrenal glands, thyroid, bone marrow, and spleen in an autopsy study of eight people who were severely immunocompromised at the time of death. The amount of HCV produced from these sites appeared to be relatively low. The clinical significance of extrahepatic HCV is not fully understood, and it is difficult to definitively determine the presence of replication in the absence of an in vivo model. In a recent publication, Laskus documented evidence of HCV replication in peripheral blood cells (monocytes/macrophages, and T and B cells) in HCV/HIV coinfected patients. He suggests that HCV may replicate in the same cells infected with HIV and that there may be direct interactions between the two viruses (Laskus 2000). These data, however, have yet to be confirmed.
HCV production on a daily basis can be very high. HCV production can be as high as 1 x 1012 virions (one trillion) per day (Neumann 1998). Average HCV RNA levels (viral load) in people coinfected with HIV have been reported to be as high as 16.8 million copies per milliliter (mL) (Mika 1999). The half-life of an HCV virus is about 2.7 days (Neumann 1998).
Thomas and colleagues studied HCV RNA levels in 969 HCV-infected people, 468 with HIV and 501 without (Thomas 2000). They found that factors associated with lower average HCV RNA levels in the HIV-negative group included younger age, ongoing hepatitis B infection, and the absence of needle sharing. In the HCV/HIV coinfected group, no differences in HCV RNA levels were correlated with age, race, gender, or alcohol or drug use:
Mean HCV RNA Level in Patients with and without HIV
In HIV/HCV coinfected individuals, HCV RNA levels are observed to increase after the second day of IFN treatment even though there was a rapid decrease the first day. One interpretation of this observation is that while HIV coinfection does not interfere with IFN's ability to reduce HCV production, HIV infection may interfere with the eradication of infected hepatocytes (Mika 1999). This hypothesis, however, is very speculative.
Comparative Viral Kinetics
Daily dosing of IFN, or the use of experimental IFNs with longer half-lives, such as pegylated-interferons, has been suggested as a way to increase the efficacy of therapy for HCV, due to the very large number of virions produced each day and the rebound in production which occurs on day two after IFN therapy (Zeuzem 1999). (See "HCV Treatments" chapter.) The changes in HCV RNA levels after the first four weeks correlate with the chance of obtaining a sustained response to therapy (Walsh 1998). Thus, kinetics studies are not only of academic interest, but may help design more rational therapy and predict earlier who might benefit from continued therapy.
Immune Responses to HCV Infection
Studies have shown that neutralizing antibodies are produced during HCV infection, but they do not appear to be protective against re-infection in humans or in chimpanzees (Ferrari 1999). The more critical determinant of the outcome of HCV infection seems to be the cell-mediated immune response, or the T-cell (CD4) response. People who are able to spontaneously clear HCV from their body have evidence of strong T-cell responses. Conversely, people who are chronically infected with HCV do not appear to either mount a strong T-cell response early after HCV infection, or maintain an initial strong T-cell response to HCV antigens (Gerlach 1999). In Gerlach's study, the 20 people (52.6%) out of 38 studied who cleared HCV infection all had a strong and sustained antiviral T-cell response to HCV, while the people who became chronically infected either showed no initial T-cell response (12, 31.6%) or did not maintain an initial strong antiviral T-cell response (6, 15.8%).
Over time, however, in most people chronically infected with HCV, T-cell responses increase but are not able to clear HCV. Ferrari and colleagues write that:
More information about the immune events taking place within the inflamed liver is required to draw a more reliable picture of HCV pathogenesis and to create the ground for more effective strategies of prevention and treatment of HCV infection. (Ferrari 1999)
Another limitation of current research is the lack of necessary cell culture systems and animal models to study the many complex factors involved in the immunologic responses to HCV infection (Cerny 1999).
Possible Strategies for a Virus to Escape Immune Elimination
Generally neither HCV RNA levels nor alanine aminotransferase (ALT) levels (liver enzyme levels) correlate very well with the extent of liver damage seen on biopsy. Gretch and colleagues, however, have reported that replication of HCV in human liver tissue shows a significant correlation with the severity of HCV infection. They reported a very strong correlation with the percentage of human liver tissues cells infected with HCV in vitro, and the degree of hepatic inflammation (Gretch 1999). They suggest that the amount of damage to the liver may be a factor of the process of HCV replication, not merely the presence of HCV in the liver.
Arguments Supporting the Relevance of Immune-mediated Liver Cell Damage in HCV Infection
While HCV is an RNA virus, it is not a retrovirus; therefore, HCV does not incorporate its genetic code into the host cell's DNA. So if all infected liver cells, or hepatocytes, and any other cells in the body which are infected with HCV die -- and there are no free HCV virions around to infect new cells-then the person will no longer be infected with HCV (i.e., the infection will be eradicated). Some investigators believe that most people who remain without detectable HCV RNA six months after therapy have achieved eradication (i.e., they are cured). (See "HCV Treatments" chapter.) Approximately 15% of people acutely infected with HCV are able to achieve life-long eradication of HCV from their body by their immune response. (See "HCV Natural History" chapter.) Whether people are in fact cured will require longer follow-up; however, there is an important implication to achieving eradication. People can be re-infected with HCV after they have had the initial HCV infection eradicated; there is no life-long HCV immunity (Farci 1992).
Extrahepatic Manifestations of HCV
While the primary site of clinical infection with HCV is the liver, a significant number of people develop disease symptoms at sites other than the liver, referred to as extrahepatic manifestations of chronic HCV infection. A recent report reviewed sites of HCV infection in 1,604 patients infected with HCV; it found that 74% of people had at least one extrahepatic manifestation of HCV infection (Cacoub 1999). The most common manifestations were:
The report also noted some laboratory abnormalities such as cryoglobulinemia (increase in a certain type of "cold" antibody in the blood), antinuclear antibodies, low thyroxine (thyroid enzyme) levels, and anti-smooth-muscle antibodies. A multivariate analysis demonstrated that the following factors were associated with an increased incidence of extrahepatic manifestations:
Another study reported that 38% (122/321) of people with HCV infection had at least one extrahepatic manifestation, including joint pains (19%), skin changes (17%), dry mucous membranes (12%), and sensory nerve changes (9%). Thus, the most common symptoms involved the joints and skin. HCV/HIV coinfection was associated with an increased incidence of low platelet counts (thrombocytopenia) and autoantibodies (antibodies against body tissues) (Cacoub 2000).
All of these symptoms and laboratory abnormalities are typically seen in people with autoimmune diseases, or people with diseases that are the result of their own immune system attacking components of their own body. This observation provides additional support to the belief that much of the damage observed due to HCV infection is actually a result of an overactive immune system, or an immune system that is mistakenly attacking components in the body as it attempts to attack HCV.
The pathogenesis, viral dynamics, and immunologic response of HCV remain incompletely understood. Reliable and efficient cell culture systems and a small-animal model are needed to better understand these areas. It is hoped that further advancement in this field will lead to novel therapeutic agents to treat and cure patients with HCV.
Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 42:2204-12, 1999.
This article was provided by Treatment Action Group. It is a part of the publication The Hepatitis Report.